Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Karl Bayer to Animals

This is a "connection" page, showing publications Karl Bayer has written about Animals.

 
Connection Strength
 
 
 
1.315
 
  1. Larsen ME, Rumian NL, Quillinan N, Bayer KU. CaMKII mechanisms that promote pathological LTP impairments. Curr Opin Neurobiol. 2025 Jun; 92:102961.
    View in: PubMed
    Score: 0.051
  2. Brown CN, Chao FY, Quang D, Rumian NL, Kleinjan MS, Coultrap SJ, Bayer KU. A? impairs the LTP-related movement of endogenous CaMKII but not of exogenous GFP-CaMKII. Mol Biol Cell. 2025 May 01; 36(5):ar60.
    View in: PubMed
    Score: 0.051
  3. Brown CN, Blaine RE, Barker CM, Coultrap SJ, Bayer KU. The neuroprotective ?-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIa autophosphorylation at T286 or binding to GluN2B. Mol Pharmacol. 2025 Apr; 107(4):100029.
    View in: PubMed
    Score: 0.051
  4. Bayer KU, Giese KP. A revised view of the role of CaMKII in learning and memory. Nat Neurosci. 2025 Jan; 28(1):24-34.
    View in: PubMed
    Score: 0.050
  5. Rumian NL, Barker CM, Larsen ME, Tullis JE, Freund RK, Taslimi A, Coultrap SJ, Tucker CL, Dell'Acqua ML, Bayer KU. LTP expression mediated by autonomous activity of GluN2B-bound CaMKII. Cell Rep. 2024 10 22; 43(10):114866.
    View in: PubMed
    Score: 0.049
  6. Tullis JE, Bayer KU. Induction of LTP mechanisms in dually innervated dendritic spines. Sci Rep. 2024 07 09; 14(1):15855.
    View in: PubMed
    Score: 0.048
  7. Brown CN, Bayer KU. Studying CaMKII: Tools and standards. Cell Rep. 2024 04 23; 43(4):113982.
    View in: PubMed
    Score: 0.047
  8. Rumian NL, Freund RK, Dell'Acqua ML, Coultrap SJ, Bayer KU. Decreased nitrosylation of CaMKII causes aging-associated impairments in memory and synaptic plasticity in mice. Sci Signal. 2023 07 25; 16(795):eade5892.
    View in: PubMed
    Score: 0.045
  9. Rumian NL, Brown CN, Hendry-Hofer TB, Rossetti T, Orfila JE, Tullis JE, Dwoskin LP, Buonarati OR, Lisman JE, Quillinan N, Herson PS, Bebarta VS, Bayer KU. Short-term CaMKII inhibition with tatCN19o does not erase pre-formed memory in mice and is neuroprotective in pigs. J Biol Chem. 2023 05; 299(5):104693.
    View in: PubMed
    Score: 0.044
  10. Cook SG, Rumian NL, Bayer KU. CaMKII T286 phosphorylation has distinct essential functions in three forms of long-term plasticity. J Biol Chem. 2022 09; 298(9):102299.
    View in: PubMed
    Score: 0.042
  11. Rumian NL, Chalmers NE, Tullis JE, Herson PS, Bayer KU. CaMKIIa knockout protects from ischemic neuronal cell death after resuscitation from cardiac arrest. Brain Res. 2021 12 15; 1773:147699.
    View in: PubMed
    Score: 0.040
  12. Goodell DJ, Tullis JE, Bayer KU. Young DAPK1 knockout mice have altered presynaptic function. J Neurophysiol. 2021 05 01; 125(5):1973-1981.
    View in: PubMed
    Score: 0.039
  13. Tullis JE, Rumian NL, Brown CN, Bayer KU. The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting. PLoS One. 2020; 15(7):e0236478.
    View in: PubMed
    Score: 0.037
  14. Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
    View in: PubMed
    Score: 0.035
  15. Bayer KU, Schulman H. CaM Kinase: Still Inspiring at 40. Neuron. 2019 08 07; 103(3):380-394.
    View in: PubMed
    Score: 0.034
  16. Cook SG, Goodell DJ, Restrepo S, Arnold DB, Bayer KU. Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. Cell Rep. 2019 04 16; 27(3):658-665.e4.
    View in: PubMed
    Score: 0.034
  17. Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIa and ? splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Sci Rep. 2018 04 03; 8(1):5448.
    View in: PubMed
    Score: 0.031
  18. Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the depalmitoylation and synaptic removal of the scaffold protein AKAP79/150 to mediate structural long-term depression. J Biol Chem. 2018 02 02; 293(5):1551-1567.
    View in: PubMed
    Score: 0.031
  19. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243.
    View in: PubMed
    Score: 0.030
  20. Goodell DJ, Benke TA, Bayer KU. Developmental restoration of LTP deficits in heterozygous CaMKIIa KO mice. J Neurophysiol. 2016 11 01; 116(5):2140-2151.
    View in: PubMed
    Score: 0.028
  21. Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B Protein Interaction Maintains Synaptic Strength. J Biol Chem. 2016 07 29; 291(31):16082-9.
    View in: PubMed
    Score: 0.028
  22. Barcomb K, Goodell DJ, Arnold DB, Bayer KU. Live imaging of endogenous Ca??/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity. J Neurochem. 2015 Nov; 135(4):666-73.
    View in: PubMed
    Score: 0.026
  23. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9.
    View in: PubMed
    Score: 0.024
  24. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7.
    View in: PubMed
    Score: 0.023
  25. Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, Bayer KU. Excitotoxic glutamate insults block autophagic flux in hippocampal neurons. Brain Res. 2014 Jan 13; 1542:12-9.
    View in: PubMed
    Score: 0.023
  26. Barcomb K, Coultrap SJ, Bayer KU. Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol. 2013 Dec; 84(6):834-43.
    View in: PubMed
    Score: 0.023
  27. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012 Oct; 35(10):607-18.
    View in: PubMed
    Score: 0.021
  28. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72.
    View in: PubMed
    Score: 0.020
  29. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20.
    View in: PubMed
    Score: 0.018
  30. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
    View in: PubMed
    Score: 0.018
  31. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7.
    View in: PubMed
    Score: 0.018
  32. Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett. 2009 Nov 19; 583(22):3577-81.
    View in: PubMed
    Score: 0.017
  33. Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell. 2007 Dec; 18(12):5024-33.
    View in: PubMed
    Score: 0.015
  34. O'Leary H, Lasda E, Bayer KU. CaMKIIbeta association with the actin cytoskeleton is regulated by alternative splicing. Mol Biol Cell. 2006 Nov; 17(11):4656-65.
    View in: PubMed
    Score: 0.014
  35. O'Leary H, Sui X, Lin PJ, Volpe P, Bayer KU. Nuclear targeting of the CaMKII anchoring protein alphaKAP is regulated by alternative splicing and protein kinases. Brain Res. 2006 May 01; 1086(1):17-26.
    View in: PubMed
    Score: 0.014
  36. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006 Jan 25; 26(4):1164-74.
    View in: PubMed
    Score: 0.013
  37. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7.
    View in: PubMed
    Score: 0.011
  38. Buonarati OR, Miller AP, Coultrap SJ, Bayer KU, Reichow SL. Conserved and divergent features of neuronal CaMKII holoenzyme structure, function, and high-order assembly. Cell Rep. 2021 12 28; 37(13):110168.
    View in: PubMed
    Score: 0.010
  39. Bayer KU, Schulman H. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):917-23.
    View in: PubMed
    Score: 0.010
  40. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001 Jun 14; 411(6839):801-5.
    View in: PubMed
    Score: 0.010
  41. Chalmers NE, Yonchek J, Steklac KE, Ramsey M, Bayer KU, Herson PS, Quillinan N. Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice. Mol Neurobiol. 2020 Jan; 57(1):150-158.
    View in: PubMed
    Score: 0.009
  42. Bayer KU, L?hler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Res Mol Brain Res. 1999 Jun 18; 70(1):147-54.
    View in: PubMed
    Score: 0.009
  43. Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. EMBO J. 1998 Oct 01; 17(19):5598-605.
    View in: PubMed
    Score: 0.008
  44. Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives A? Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 06 12; 23(11):3137-3145.
    View in: PubMed
    Score: 0.008
  45. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742.
    View in: PubMed
    Score: 0.007
  46. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117.
    View in: PubMed
    Score: 0.007
  47. Dosemeci A, Toy D, Burch A, Bayer KU, Tao-Cheng JH. CaMKII-mediated displacement of AIDA-1 out of the postsynaptic density core. FEBS Lett. 2016 09; 590(17):2934-9.
    View in: PubMed
    Score: 0.007
  48. Bayer KU, L?hler J, Harbers K. An alternative, nonkinase product of the brain-specifically expressed Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. Mol Cell Biol. 1996 Jan; 16(1):29-36.
    View in: PubMed
    Score: 0.007
  49. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. NMDA-induced accumulation of Shank at the postsynaptic density is mediated by CaMKII. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):808-11.
    View in: PubMed
    Score: 0.006
  50. Thein S, Pham A, Bayer KU, Tao-Cheng JH, Dosemeci A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):550-4.
    View in: PubMed
    Score: 0.006
  51. Bernard PB, Castano AM, Bayer KU, Benke TA. Necessary, but not sufficient: insights into the mechanisms of mGluR mediated long-term depression from a rat model of early life seizures. Neuropharmacology. 2014 Sep; 84:1-12.
    View in: PubMed
    Score: 0.006
  52. Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP. NMDA receptor activation strengthens weak electrical coupling in mammalian brain. Neuron. 2014 Mar 19; 81(6):1375-1388.
    View in: PubMed
    Score: 0.006
  53. Thein S, Tao-Cheng JH, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One. 2014; 9(3):e91312.
    View in: PubMed
    Score: 0.006
  54. Liu X, Liu Y, Zhong P, Wilkinson B, Qi J, Olsen CM, Bayer KU, Liu QS. CaMKII activity in the ventral tegmental area gates cocaine-induced synaptic plasticity in the nucleus accumbens. Neuropsychopharmacology. 2014 Mar; 39(4):989-99.
    View in: PubMed
    Score: 0.006
  55. Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-a1 and -a2 at the postsynaptic density. PLoS One. 2013; 8(8):e71795.
    View in: PubMed
    Score: 0.006
  56. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience. 2013 Aug 06; 244:188-96.
    View in: PubMed
    Score: 0.006
  57. Loweth JA, Li D, Cortright JJ, Wilke G, Jeyifous O, Neve RL, Bayer KU, Vezina P. Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition. J Neurosci. 2013 Jan 23; 33(4):1411-6.
    View in: PubMed
    Score: 0.005
  58. Boguslavsky S, Chiu T, Foley KP, Osorio-Fuentealba C, Antonescu CN, Bayer KU, Bilan PJ, Klip A. Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles. Mol Biol Cell. 2012 Oct; 23(20):4065-78.
    View in: PubMed
    Score: 0.005
  59. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci. 2011 Jun 22; 31(25):9170-8.
    View in: PubMed
    Score: 0.005
  60. Marsden KC, Shemesh A, Bayer KU, Carroll RC. Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proc Natl Acad Sci U S A. 2010 Nov 23; 107(47):20559-64.
    View in: PubMed
    Score: 0.005
  61. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, Rossi G, Vitale M. Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem. 2003 Nov 14; 278(46):45101-8.
    View in: PubMed
    Score: 0.003
  62. Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, Meyer T. Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron. 2003 Jul 17; 39(2):283-97.
    View in: PubMed
    Score: 0.003
  63. Nori A, Lin PJ, Cassetti A, Villa A, Bayer KU, Volpe P. Targeting of alpha-kinase-anchoring protein (alpha KAP) to sarcoplasmic reticulum and nuclei of skeletal muscle. Biochem J. 2003 Mar 15; 370(Pt 3):873-80.
    View in: PubMed
    Score: 0.003
  64. Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H, Hell JW. Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem. 2002 Dec 13; 277(50):48441-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)